Drug
Ioversol 320 Mgi
Ioversol 320 Mgi: highest development phase Post-Market, developed by Guerbet. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Guerbet
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ioversol 320 mgI/mL NCT00793182 | Post-Market | Renal Impairment |
Latest
No recent events.
Follow Ioversol 320 Mgi on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.